Ascelia Pharma – Presentation of FY 2025 results

You can already sign up for the event and submit your questions. You don’t need to attend live to send in your questions for the presentation.

Ascelia Pharma is expected to release its full-year 2025 results on 5 February 2026. Join us for a live presentation with CEO Magnus Corfitzen from Ascelia Pharma the following day at 13:00, where he will present the financial results for 2025 and provide an update on the company’s latest developments.

During 2025, Ascelia Pharma reached a key milestone with the submission of the New Drug Application (NDA) for Orviglance to the FDA. Following the Q3 results, the FDA formally accepted the NDA for review and communicated a PDUFA date of 3 July 2026, confirming that the application is sufficiently complete to proceed through the regulatory evaluation process. In connection with the Q3 report, the company reiterated that they expect cash runway into Q4 2026, beyond the communicated PDUFA date, and reduced near-term funding risk.

In addition to the financial results, the presentation is expected to include a discussion on ongoing partnering activities related to Orviglance, which remains a key strategic focus for Ascelia Pharma ahead of a potential approval.

About Ascelia Pharma
Ascelia Pharma is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. Ascelia Pharma has two drug candidates in clinical development – Orviglance® (Mangoral) and Oncoral. The company is headquartered in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE).

Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a Digital IR/Corporate Visibility subscription agreement / Michael Friis, 15.24, 5 January 2026. (Updated 16.04, 22 January 2026)